Welcome to Pharmaxis

Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval.  

Company Highlights

Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate

Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired  the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.

Pharmaxis releases interim results for phase I clinical trial of SSAO/VAP-1 inhibitor PXS4728A

Pharmaxis has announced positive interim results from the single ascending dose stage of the Phase 1 clinical trial for its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor PXS4728A.

Pharmaxis signs second agreement with Chiesi

Pharmaxis has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) for cystic fibrosis in adults aged 18 years and above in Germany, the United Kingdom and Ireland.

Pharmaxis announces completion of restructuring and new focus on partnering

Pharmaxis is pleased to announce its transition to a strategic business plan with an increased focus on innovation and partnering in order to generate value.

LATEST NEWS & PUBLICATIONS